AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03308734 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced-Exertion High-Intensity Interval Training
Description: The 6-week REHIT protocol will involve 3 training sessions a week. Each session will include 10 minutes of unloaded pedalling using a cycle ergometer. Volunteers will be asked to increase to their maximal pedal frequency possible for 1-2 seconds prior to applying a resistance of 5 % of pre-training body weight for the Wingate sprint. The sprints will take place at 2 minutes and at 6 minutes. Sprint duration will be increased from 10 seconds in the first week to 15 seconds in the second and third weeks and finally 20 seconds in the remaining weeks. Patients will receive strong verbal encouragement during the sprints after which the resistance will be removed.
Study NCT03031678 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Electric-Acoustic Stimulation (EAS) Cochlear Implant System
Description: Combination of a cochlear implant and a hearing aid
Study NCT04073589 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARGX-113 with rHuPH20
Description: subcutaneous administration of efgartigimod with recombinant human hyaluronidase PH20 (rHuPH20)
Study NCT01794884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: 20% N(2)-L-alanyl-L-glutamine 0.4g/kg(2ml/kg) mixed with compound amino acid (10ml/kg).Intravenous injection twice (24 hours、1 hour before operation). Injection rate = 6ml/kg/h
Study NCT01794884 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ringer's solution
Description: Ringer's solution 12ml/kg. Intravenous injection twice (24 hours、1 hour before operation). Injection rate = 6ml/kg/h.
Study NCT01756547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Citrate
Description: Potassium citrate, oral solution contains Tripotassium citrate monohydrate 20 grams, Citric acid monohydrate 4 grams, distilled water 40 ml, and simple syrup 100ml. The solution contained in a bottle of glass that contains 20 ml of 2 meq/ml of potassium and 2.5 meq/ml of citrate. The dose is 0,3ml/kg/day of the solution until the 38-40 weeks of corrected gestational age or unacceptable toxicity develops.
Study NCT01756547 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03726853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator placebo
Description: Comparator placebo
Study NCT01686529 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autoconjunctival grafting
Description: The pterygium head was lifted off the corneal surface by blunt dissection. The pterygium body was dissected from the underlying sclera and thereafter excised. A thorough removal of Tenon's capsule was performed in an area much greater than the pterygium body. Free conjunctival autografting after pteryigum excision was performed as follows: the desired size of the conjunctiva under the upper eyelid was marked and excised. No limbal tissue was included in the graft. The excised tissue was placed on the bare sclera and tightly sutured to the sclera and the limbal area. Finally the autograft edges were sutured to the conjunctiva all around.
Study NCT01686529 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autoconjunctival grafting
Description: The pterygium head was lifted off the corneal surface by blunt dissection. The pterygium body was dissected from the underlying sclera and thereafter excised. A thorough removal of Tenon's capsule was performed in an area much greater than the pterygium body. Free conjunctival autografting after pteryigum excision was performed as follows: the desired size of the conjunctiva under the upper eyelid was marked and excised. No limbal tissue was included in the graft. The excised tissue was placed on the bare sclera and tightly sutured to the sclera and the limbal area. Finally the autograft edges were sutured to the conjunctiva all around.
Study NCT01686529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subconjuntival bevacizumab injection
Description: The subconjunctival injection of bevacizumab was applied adjacent to the site of pterygium separation inside the healthy conjunctiva. The half of the dose (1.25 mg/0.05ml) was applied in the nasal inferior quadrant, and the other half of the dose was applied in the nasal superior quadrant.
Study NCT02956421 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RABIPUR®
Description: Biological rabies vaccine
Study NCT02956421 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PIKA rabies vaccine
Description: Biological rabies vaccine
Study NCT02821988 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonography for Biophysical profile
Study NCT00817037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitaxsentan
Description: Sitaxsentan 100mg once daily oral dosing for 6 weeks
Study NCT00817037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: Nifedipine 30mg once daily oral dosing for 6 weeks
Study NCT00817037 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet once daily oral dosing for 6 weeks
Study NCT01325584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven
Description: initial dose of 0.1 g/kg body weight (1ml/kg) and increased to 0.2 g/kg body weight (2ml/kg) on day 2 or 3 of treatment. The infusion rate will not exceed 0.5mL Omegaven/kg body weight/hr (corresponding to 0.05g fish oil/kg/hr). Patients will receive the initial infusion of PN containing Omegaven at Midwestern Regional Medical Center (MRMC) in the infusion center to observe for adverse reactions. Patients will continue to receive infusions at MRMC for the first 2 to 3 days of dosing. After tolerance is established, patients will receive treatment at home. All study patients will have a Screening Visit; Day 1, Day 2 and Day 3 visits; and weekly visits for one month.
Study NCT03952104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Strength training
Study NCT06177587 — intervention group
Intervention type: OTHER
Intervention: Assesment of biomarkers in acute coronary syndromes
Description: Collection of 20ml of blood from peripheral vein.
Study NCT01343498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235
Description: BEZ235 will be given on a dose-escalation design, beginning at 200 mg BID (SDS sachet) in 3 patients and progressing to 400 mg, 600 mg, and 800 mg respectively based on tolerability.
Study NCT01305902 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: contingency management
Description: Participants assigned to the experimental group will earn chances to win prizes if they have walked the recommended number of steps.
Study NCT03726853 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator placebo
Description: Comparator placebo
Study NCT04383223 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iTransition
Description: Is a mobile website application (app), and it can be used on a range of devices (computer, tablet, smartphone) and operating systems (iOS, Android, Windows). Features of iTransition will include, but are not limited to: medication reminders, calendar tracking of appointments, direct messaging between youth and providers, and privacy password lock.
Study NCT05541952 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: Revaccination with BCG, using the immunobiological used in the Brazilian public health network, strain Russia.
Study NCT00929799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human Growth Hormone (Genotropin® )
Description: Once daily by subcutaneous injection using a Genotropin pen in the abdomen at 22:00 h. Maximal GH dose of 0.003 mg/kg/day.
Study NCT04449575 — intervention group
Intervention type: OTHER
Intervention: eSwabs
Description: from skin
Study NCT02684916 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chiropractic treatment
Description: The child receives chiropractic manipulation treatment in the neck and in the spine and pelvis according to individual needs. They also receive a written list of general advice regarding lifestyle and habits.~The parents and the child are unaware of group allocation.
Study NCT02684916 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-therapeutic placebo treatment: a broad non-specific contact outside the spinal column is taken on subject's scapula and gluteal region lying in a side posture position, on the scapulae in a prone position and on trapezius muscles in a sitting position. In those positions the chiropractor pushes in a non-intentional and non- therapeutic directional line with a low-amplitude, low velocity push maneuver. All contacts are performed without soft tissue pre-tension and gentle contact, to insure that no joint cavitation occurs. To obtain a noise that many people associate with a chiropractic spinal adjustment, a de-activated Activator Instrument is used on the arm of the chiropractor to give a click-sound. General advice on lifestyle and habits is handed out to the placebo group as well.
Study NCT02704715 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: general anesthesia,orbital operation
Description: to evaluate the pain under general anesthesia
Study NCT03641924 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cognitive Processing Therapy
Description: Cognitive Processing Therapy is an evidence-based psychotherapy for PTSD.
Study NCT02881437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IgHy10
Description: Sub Cutaneous IgHy10 administration
Study NCT00403234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear.
Study NCT00403234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.
Study NCT00403234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine transdermal patches 10 mcg/h and 20 mcg/h (total of 30 mcg/h) applied for 7-day wear.
Study NCT00403234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo BTDS
Description: Placebo to match BTDS transdermal 10 and 20 patches applied for 7-day wear.
Study NCT00784498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine/Midazolam
Description: Intravenous bolus of midazolam 0.1mg/kg in titrated dose of 1 mg/min until spontaneous eye closure or up to 5mg (whichever comes first) followed by ketamine 0.5-1mg/kg (up to 100mg) in titrated dose of 10mg/30 seconds, to achieve the desired level of sedation
Study NCT00784498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Intravenous bolus of propofol 0.5-1mg/kg in titrated dose of 10mg/30seconds (up to 100mg) to achieve the desired level of sedation
Study NCT01897454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT01897454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT01897454 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT01897454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT01897454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT01897454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT01361152 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anatomic modular fixed-bearing
Description: anatomic modular (AMK; DePuy) fixed-bearing prosthesis
Study NCT01361152 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low contact stress rotating platform mobile-bearing
Description: low contact stress rotating platform (LCS RP; DePuy) mobile-bearing prosthesis
Study NCT01542125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Lidocaine
Description: 4% Liposomal Lidocaine
Study NCT01542125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tubes were visually identical to the Liposomal Lidocaine tubes.
Study NCT01372267 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation for substance abuse
Description: This active control provides detailed educational information about substance use and chronic pain to those enrolled.
Study NCT01372267 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for pain in Substance abuse
Description: The therapeutic intervention group is designed to provide beneficial coping strategies that are helpful in dealing with both substance use and pain.
Study NCT02176499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan, low dose
Study NCT02176499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan, high dose
Study NCT02176499 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02176499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT04250883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low intra-abdominal pressure
Description: 8 mmHg
Study NCT04250883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (NMB)
Description: Deep NMB (PTC1-2)
Study NCT04250883 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard intra-abdominal pressure
Description: 14 mmHg
Study NCT04250883 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate neuromuscular blockade (NMB)
Description: Moderate NMB (TOF 1-2)
Study NCT03464305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Description: Patients treated with acetylsalicylic acid 80 mg once daily for 5 years. Patients will be stratified according to the admission of adjuvant chemotherapy.
Study NCT03464305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients treated with placebo. Patients will be stratified according to the admission of adjuvant chemotherapy.
Study NCT00982137 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated Japanese encephalitis virus; Yellow fever virus
Description: ChimeriVax™-JE, 0.5 mL, Subcutaneous on Day 0; STAMARIL®, 0.5 mL, Subcutaneous on Day 30.
Study NCT00906334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ON 01910.Na
Description: The original dosing regimen was 800 mg/m\^2 ON 01910.Na.
Study NCT00906334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ON 01910.Na
Description: Per Amendment 3 to the Protocol, the dosing regimen was changed to 1800 mg ON 01910.Na. Patients enrolled at the original dosing regimen could choose to remain in the original regimen or switch to the new regimen.
Study NCT02648932 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Haplo-Cord Transplant
Description: For conditioning regimens, haplo-identical grafts will be selected by the Miltenyi Device
Study NCT02648932 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Matched Unrelated Donor Transplant
Study NCT04001127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Functional Training
Description: The exercise intervention for this study will be HIFT, defined as a style of training that incorporates functional, multimodal movements, performed at relatively high intensity, and designed to improve parameters of general physical fitness and performance. The program design and template will be based on the principles of the HIFT program called CrossFit®. CrossFit is described as a strength and conditioning program that focuses on constantly varying functional movements, performed at a relatively high intensity. CrossFit training includes a variety of elements from gymnastics (e.g., floor, bar and ring exercises), weightlifting exercises (e.g., squats, cleans, snatches and presses with a barbell, dumbbell or kettlebell), and cardiovascular activities (e.g., running or rowing).
Study NCT00054665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS-341
Description: 1.3 mg/m\^2 intravenous injection days 1, 4, 8, 11 every 3 weeks
Study NCT00054665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 50 mg/m\^2 day continuous intravenous infusion (CIV) days 1-4, 96 hour infusion. Repeat cycle every 21 days.
Study NCT00054665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 10 mg/m\^2 day CIV days 1-4, 96 hour infusion. Repeat cycle every 21 days.
Study NCT00982137 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow fever virus; Live attenuated Japanese encephalitis virus
Description: STAMARIL®, 0.5 mL Subcutaneous on Day 0; ChimeriVax™-JE, 0.5 mL Subcutaneous on Day 30.
Study NCT00982137 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated Japanese encephalitis virus; Yellow fever virus
Description: ChimeriVax™-JE, 0.5 mL Subcutaneous and STAMARIL®, 0.5 mL, Subcutaneous on Day 0; Diluent 0.5 mL, Subcutaneous on Day 30.
Study NCT02702284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advance Directives
Description: These subject's will have a research assistant (RA) review and walk through the advance directives brochure. The RA will read all of the brochure to the patient and prompt for questions. In addition, a link to an educational video on advance directives. The advance directive link will be either texted or emailed or given in paper per the subject's preference.
Study NCT02702284 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Advance Directives without assistance
Description: This group of subjects will be provided with the advance directive and then referred to clinic staff for assistance.
Study NCT00895908 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Friendship Group
Description: Social skills training for 30 sessions, held twice per week over 4 to 5 months
Study NCT00895908 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Academic tutoring
Description: Tutoring to support emergent literacy skills, held 1 to 2 times per week over 4 months
Study NCT00351390 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Drug therapy for HF
Description: Titration of HF meds in an aggressive out patient manner following guideline direction
Study NCT00351390 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NT-proBNP guided HF therapy
Description: Standard of care drug therapy following guideline direction, plus adjustment of medication titrated to achieve NT-proBNP \<1000 pg/mL
Study NCT00794469 — intervention group
Intervention type: OTHER
Intervention: Water
Description: Children will drink 10 cc/kg of cold water(4 degrees centigrade)
Study NCT02853123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: fixed dose combination once daily
Study NCT02853123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol
Description: fixed dose combination once daily
Study NCT02853123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Study NCT00902057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desmopressin
Description: single desmopressin subcutaneous injection, 1.5mcg
Study NCT00902057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desmopressin
Description: single desmopressin subcutaneous injection, 3mcg
Study NCT00902057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desmopressin
Description: single desmopressin subcutaneous injection, 15mcg
Study NCT00902057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: saline subcutaneous
Study NCT00564603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Sodium Phosphate Injection
Description: Dexamethasone, 10mg, continuously infused up to 48h after surgeries.
Study NCT00564603 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: Saline, in same volume of 2mL
Study NCT00839436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT107
Study NCT02365805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel
Description: Epirubicin 90 mg/m2 + Ciclofosfamide 600 mg/m2 + 5-Fluorouracil 600 mg/m2 intravenous infusion on day 1 every three weeks, for four cycles; followed by Paclitaxel 100 mg/m2 weekly for eight weeks.
Study NCT02365805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin + Cisplatin + Fluorouracil
Description: Epirubicin 60 mg/m2 + Cisplatin 60 mg/m2 intravenous infusion on day 1 every three weeks and 5-Fluorouracil 200 mg/m2/day for eight cycles.
Study NCT02365805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel + Ciclofosfamide
Description: Docetaxel 75 mg/m2 + Ciclofosfamide 600 mg/m2, intravenous infusion on day 1 every three weeks, for eight cycles.